ScandiDos (SDOS) Q3 2025 earnings summary

Executive summary

• Realized cost savings and maintained cost control drove significant profitability improvement both quarterly and over nine months.

• Sales delivered to 14 countries, with broad geographic demand for leading QA solutions in radiotherapy.

• Profitability focus resulted in another profitable quarter, despite slightly pressured gross margins due to higher distributor market share.

• Asia showed positive development, especially India, while China and North America were weaker than expected.

• Hospital Central de la Defensa Gómez Ulla in Madrid named as a reference center for ScandiDos and Delta4 product family.

Financial highlights

• Net sales for Q3 amounted to SEK 17.7m, down 1% compared to Q3 last year; nine-month sales up 2% to SEK 46.6m.

• Gross margin for Q3 was 74% (77% last year); nine-month gross margin at 73% (76%).

• EBITDA for Q3 improved to SEK 1.5m (SEK 0.8m last year); nine-month EBITDA at SEK 2.6m (SEK -4.5m last year).

• Net income for Q3 was SEK 1.1m (SEK -0.2m last year); nine-month net income SEK 0.9m (SEK -7.0m last year).

• Earnings per share for Q3 and nine months: SEK 0.02 (Q3 last year: SEK 0.00; nine months last year: SEK -0.15).

Outlook and guidance

• Continued expansion of advanced radiotherapy supports ongoing demand for advanced measurement systems.

• Investments in technology leadership and market presence in promising geographies expected to drive future growth.